Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T11:01:49.075Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-Term Fluoxetine Treatment of Bulimia Nervosa

Published online by Cambridge University Press:  02 January 2018

David J. Goldstein ,
Michael G. Wilson ,
Vicki L. Thompson ,
Janet H. Potvin ,
Alvin H. Rampey Jr  and
The Fluoxetine Bulimia Nervosa Research Group
David J. Goldstein*
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
Michael G. Wilson
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
Vicki L. Thompson
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
Janet H. Potvin
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
Alvin H. Rampey Jr
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
The Fluoxetine Bulimia Nervosa Research Group
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
*
Dr David Goldstein, Lilly Research Laboratories, Lilly Corporate Center 2128, Indianapolis, Indiana 46285, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

A large collaborative 8-week study has shown fluoxetine to be effective and safe in treating patients with bulimia nervosa. The present study evaluated fluoxetine over 16 weeks.

Method

Fifteen US out-patient psychiatry clinics conducted a double-blind parallel study in men and women with DSM–III–R bulimia nervosa (483 patients entered, 398 randomised [3:1 ratio, fluoxetine 60 mg/day or placebo], 225 completed). Outcome measures included change in vomiting and binge-eating episodes per week, Eating Disorder Inventory, Clinical Global Impressions and Patient's Global Impression.

Results

Compared with placebo, fluoxetine treatment resulted in significantly greater reductions in vomiting (F [1,360] = 14.73, P< 0.0001) and binge-eating (F [1,360] = 14.39, P=0.0002) episodes per week at endpoint and improvement in other outcome measures. Adverse event, vital sign and laboratory analyses indicated that fluoxetine was safe.

Conclusion

Fluoxetine appeared to be safe and effective in patients with bulimia nervosa for up to 16 weeks.

Type
Papers
Information
The British Journal of Psychiatry , Volume 166 , Issue 5 , May 1995 , pp. 660 - 666
Copyright
Copyright © Royal College of Psychiatrists, 1995 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agras, W. S., Rossiter, E. M., Arnow, B., et al (1992) Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. American Journal of Psychiatry, 49, 82–87.Google Scholar
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
American Psychiatric Association (1993) Practice guideline for eating disorders. American Journal of Psychiatry, 150, 212–228.CrossRefGoogle Scholar
Cohn, J. (1977) Statistical Power Analysis for the Behavioral Sciences, p. 42. New York: Academic Press.Google Scholar
Fichter, M. M., Leibl, K., Rief, W., et al (1991) Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry, 24, 1–7.CrossRefGoogle ScholarPubMed
Fluoxetine Bulimia Nervosa Collaborative Study Group (1992) Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Archives of General Psychiatry, 49, 139–147.CrossRefGoogle Scholar
Garner, D. M., Olmsted, M. P. & Polivy, J. (1983) Eating Disorder Inventory. Odessa, Florida: Psychological Assessment Resources.Google Scholar
Goldbloom, D. S. & Olmsted, M. P. (1993) Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. American Journal of Psychiatry, 150, 770–774.Google ScholarPubMed
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare.Google Scholar
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.CrossRefGoogle ScholarPubMed
Hommel, G. (1988) A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika, 75, 383–386.CrossRefGoogle Scholar
Mantel, N. & Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22, 719–748.Google ScholarPubMed
Mitchell, J. E., Seim, H. C., Colon, E., et al (1987) Medical complications and medical management of bulimia. Annals of Internal Medicine, 107, 71–77.CrossRefGoogle ScholarPubMed
Mitchell, J. E., Pyle, R. L., Eckert, E. D., et al (1990) A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Archives of General Psychiatry, 47, 149–157.CrossRefGoogle ScholarPubMed
Mitchell, J. E., Raymond, N. & Specker, S. (1993) A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. International Journal of Eating Disorders, 14, 229–247.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
Patton, G. C. (1988) Mortality in eating disorders. Psychological Medicine, 18, 947–951.CrossRefGoogle ScholarPubMed
Pope, H. G. Jr, Champoux, R. F. & Hudson, J. I. (1987) Eating disorder and socioeconomic class: anorexia nervosa and bulimia in nine communities. Journal of Nervous and Mental Diseases, 175, 620–623.CrossRefGoogle ScholarPubMed
SAS Institute (1985) SAS User's Guide, Statistics, Version 5 Edition. Cary, NC: SAS Institute, Inc.Google Scholar
Wheadon, D. E., Rampey, A. H. Jr, Thompson, V. L., et al (1992) Lack of association between fluoxetine and suicidality in bulimia nervosa. Journal of Clinical Psychiatry, 53, 235–241.Google ScholarPubMed
Woolf, B. (1955) On estimating the relation between blood group and disease. Annals of Human Genetics, 19, 251–253.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.